Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will highlight the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, a significant challenge in drug delivery.
The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. These tiny particles could improve the delivery of drugs that are poorly soluble in water, potentially enhancing their efficacy and reducing side effects. The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial.
The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform. This AI-enabled platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration, potentially accelerating the development of new therapies.
For business leaders, this announcement underscores the growing convergence of nanotechnology and AI in drug development. The ability to intravenously deliver drugs that are currently limited by poor solubility could open new treatment avenues for cancer and other diseases, creating opportunities for partnerships and investments in nanomedicine and AI-driven biotech.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology.
The Deciparticle platform could have significant implications for the pharmaceutical industry by enabling the reformulation of existing drugs with improved delivery profiles, potentially extending patent life and creating new market opportunities. For patients, these advances could lead to more effective treatments with fewer side effects.
For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC. To view the full press release, visit https://ibn.fm/RUG7m.
